BACKGROUND: Pathophysiologic mechanisms underlying lone atrial fibrillation (AF) have not been clearly demonstrated yet. Emerging evidence has indicated that autoimmunity may play a role in the development of AF. Relationship between serum anti-M2-muscarinic receptor autoantibody (anti-M2-R) and anti-β1-adrenergic receptor autoantibody (anti-β1-R) levels and lone paroxysmal atrial fibrillation (PAF) has not been investigated. We aimed to compare anti-M2-R and anti-β1-R levels between lone PAF patients and healthy control subjects. METHODS AND RESULTS: 75 patients with lone PAF (age: 52.80 ± 6.80 years, 53 % male) and 75 healthy control subjects (age: 53.30 ± 6.80 years, 54 % male) were enrolled in the study. Serum anti-M2-R and anti-β1-R levels were measured by ELISA and compared between two groups. Anti-M2-R [142.30 (77.65-400.00) vs. 69.00 (39.48-299.04) ng/mL; p < 0.001) and anti-β1-R [102.56 (65.18-348.41) vs. 44.17 (30.89-158.54) ng/mL; p < 0.001] levels were significantly higher in patients with lone PAF compared to healthy controls. Multivariate regression analysis showed that left atrial diameter (OR: 1.471, p < 0.001), hs-CRP(OR: 1.940, p < 0.001), anti-M2-R (OR: 1.158, p < 0.001) and anti-β1-R (OR: 1.296, p < 0.001) levels were independent predictors for the presence of lone PAF. Using a cut-off level of 101.83 ng/mL, anti-M2-R levels predicted presence of lone PAF with a sensitivity of 94.68 % and specificity of 81.33 %. Anti-β1-R levels predicted presence of lone PAF with a sensitivity of 92.00 % and specificity of 73.30 %, using a cut-off level of 72.16 ng/mL. CONCLUSION: Our results demonstrated that higher serum anti-M2-R and anti-β1-R levels are associated with lone PAF. Autoantibodies related to autonomic system may play an important role in the development of lone AF.
BACKGROUND: Pathophysiologic mechanisms underlying lone atrial fibrillation (AF) have not been clearly demonstrated yet. Emerging evidence has indicated that autoimmunity may play a role in the development of AF. Relationship between serum anti-M2-muscarinic receptor autoantibody (anti-M2-R) and anti-β1-adrenergic receptor autoantibody (anti-β1-R) levels and lone paroxysmal atrial fibrillation (PAF) has not been investigated. We aimed to compare anti-M2-R and anti-β1-R levels between lone PAF patients and healthy control subjects. METHODS AND RESULTS: 75 patients with lone PAF (age: 52.80 ± 6.80 years, 53 % male) and 75 healthy control subjects (age: 53.30 ± 6.80 years, 54 % male) were enrolled in the study. Serum anti-M2-R and anti-β1-R levels were measured by ELISA and compared between two groups. Anti-M2-R [142.30 (77.65-400.00) vs. 69.00 (39.48-299.04) ng/mL; p < 0.001) and anti-β1-R [102.56 (65.18-348.41) vs. 44.17 (30.89-158.54) ng/mL; p < 0.001] levels were significantly higher in patients with lone PAF compared to healthy controls. Multivariate regression analysis showed that left atrial diameter (OR: 1.471, p < 0.001), hs-CRP(OR: 1.940, p < 0.001), anti-M2-R (OR: 1.158, p < 0.001) and anti-β1-R (OR: 1.296, p < 0.001) levels were independent predictors for the presence of lone PAF. Using a cut-off level of 101.83 ng/mL, anti-M2-R levels predicted presence of lone PAF with a sensitivity of 94.68 % and specificity of 81.33 %. Anti-β1-R levels predicted presence of lone PAF with a sensitivity of 92.00 % and specificity of 73.30 %, using a cut-off level of 72.16 ng/mL. CONCLUSION: Our results demonstrated that higher serum anti-M2-R and anti-β1-R levels are associated with lone PAF. Autoantibodies related to autonomic system may play an important role in the development of lone AF.
Authors: Dominik Linz; Arne van Hunnik; Christian Ukena; Sebastian Ewen; Felix Mahfoud; Stephan H Schirmer; Matthias Lenski; Hans-Ruprecht Neuberger; Ulrich Schotten; Michael Böhm Journal: Clin Res Cardiol Date: 2014-03-29 Impact factor: 5.460
Authors: A John Camm; Gregory Y H Lip; Raffaele De Caterina; Irene Savelieva; Dan Atar; Stefan H Hohnloser; Gerhard Hindricks; Paulus Kirchhof Journal: Europace Date: 2012-08-24 Impact factor: 5.214
Authors: P A Chiale; I Ferrari; E Mahler; M A Vallazza; M V Elizari; M B Rosenbaum; M J Levin Journal: Circulation Date: 2001-04-03 Impact factor: 29.690
Authors: Martin Greif; Franz von Ziegler; Reza Wakili; Janine Tittus; Christoph Becker; Susanne Helbig; Ruediger P Laubender; Wolfgang Schwarz; Melvin D'Anastasi; Jan Schenzle; Alexander W Leber; Alexander Becker Journal: Clin Res Cardiol Date: 2013-04-13 Impact factor: 5.460
Authors: Stavros Stavrakis; Xichun Yu; Eugene Patterson; Shijun Huang; Sean R Hamlett; Laura Chalmers; Reji Pappy; Madeleine W Cunningham; Syed A Morshed; Terry F Davies; Ralph Lazzara; David C Kem Journal: J Am Coll Cardiol Date: 2009-09-29 Impact factor: 24.094
Authors: D S Novikova; M S Bekbosynova; T Ia Antidze; N V Loladze; S P Domogatskiĭ; S P Golitsyn; E L Nasonov; I A Denisova; S P Tonevitskiĭ Journal: Kardiologiia Date: 2004 Impact factor: 0.395
Authors: Christian Pfluecke; Daniel Tarnowski; Lina Plichta; Katharina Berndt; Paul Schumacher; Stefan Ulbrich; Mathias Forkmann; Marian Christoph; David M Poitz; Carsten Wunderlich; Ruth H Strasser; Karim Ibrahim Journal: Clin Res Cardiol Date: 2015-09-28 Impact factor: 5.460